Molecular imaging of coronary plaque vulnerability using 18F-fluorocholine PET-MRI in patients with coronary artery disease

Molecular imaging of coronary plaque vulnerability using 18F-fluorocholine PET-MRI in patients with coronary artery disease - 18F-fluorocholine PET-MR imaging of coronary plaque vulnerability

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47096

Enrollment

Registered

2018-07-27

Start date

2018-03-02

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis atherosclerotic plaque inflammation in the vessel wall

Interventions

atherosclerosis

coronary

imaging

PET-MRI

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Protocol optimization (stable AP patients included at MUMC+: additional PET-MRI);* Diagnosed with stable angina pectoris and scheduled for a PCI procedure at the MUMC * Minimum age of 18 years * Mentally competent * Having provided informed written consent ;Patients included at Viecuri hospital: additional PET-MRI and OCT;* NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital * Currently stable and scheduled for another PCI at the VieCuri hospital to stent another coronary vessel * Able to visit the MUMC by own transport / train for PET-MR imaging before the new PCI procedure * Minimum age of 18 years * Mentally competent * Having provided informed written consent Patients included at MUMC+: additional PET-MRI;* Recently diagnosed with NSTEMI and scheduled for a PCI at the MUMC * GRACE risk score between 90 and 140 * Acute Coronary Syndrome (ACS) type 1 * Minimum age of 18 years * Mentally competent * Having provided informed written consent

Exclusion criteria

Exclusion criteria: * Conservatively managed patients who are not scheduled for percutaneous coronary intervention (PCI) * Patients requiring PCI

Design outcomes

Primary

Measure	Time frame
* To investigate whether vulnerable plaques on OCT (fibrous cap * 70 m) show a locally increased uptake of 18F-choline on PET-MRI compared to stable plaques. To investigate whether the culprit plaque shows a locally increased uptake of 18F-choline on PET-MRI compared to non-culprit plaques.	—

Secondary

Measure	Time frame
* To study whether there is a correlation between the uptake of 18F-choline in coronary plaques and the degree of stenosis as shown on the angiogram acquired during the PCI procedure * To study whether there is a correlation between the uptake of 18F-choline in coronary plaques and the presence of macrophages, micro-calcifications, lipid-rich necrotic core on OCT * To investigate whether there is an association between the uptake of 18F-choline in the coronary arteries and that in the carotid arteries.	—

Measure

Time frame

* To study whether there is a correlation between the uptake of 18F-choline in coronary plaques and the degree of stenosis as shown on the angiogram acquired during the PCI procedure * To study whether there is a correlation between the uptake of 18F-choline in coronary plaques and the presence of macrophages, micro-calcifications, lipid-rich necrotic core on OCT * To investigate whether there is an association between the uptake of 18F-choline in the coronary arteries and that in the carotid arteries.

—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)